Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

infections other than COVID-19 meta-analysis

Peymani, 2016 RCTchloroquine and derivativesplaceboinfections other than COVID-19high
6/4 suggested
  • suggested 76.0-fold increase in clinical improvement but with a low degree of certainty due to high risk of bias
Borges, 2013 RCTchloroquine and derivativesplaceboinfections other than COVID-19some concern
63/66 suggested
  • suggested 29.8-fold increase in clinical improvement with a moderate degree of certainty due to some concern in risk of bias
Paton, 2011
 
NCT01078779
RCTchloroquine and derivativesplaceboinfections other than COVID-19low
757/749 inconclusive
  • inconclusive 54 % increase in Influenza-like infection (PE) with a high degree of certainty due to low risk of bias
Tricou, 2010 RCTchloroquine and derivativesplaceboinfections other than COVID-19low
278/276 inconclusive

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).